Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 healthy volunteer study of IW-6463 with single ascending dose, multiple ascending dose, and food-effect cohorts
NL-OMON47937Phase 1Active, not recruiting
- Sponsor
- Cyclerion Therapeutics
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of zagociguat in Alzheimer's disease (AD) and Dementia (5 arms), sponsored by Cyclerion Therapeutics. Primary endpoints: Number of subjects with treatment-emergent adverse events in single ascending dose cohorts, Number of subjects with treatment-emergent adverse events in multiple ascending dose cohorts and 2 more. Started Jan 2019; status: active, not recruiting.
02
Drugs
zagociguat
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON47937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47937.